GREENWICH LIFESCIENCES, INC. UNDERWRITING AGREEMENT 1,260,870 Shares of Common StockUnderwriting Agreement • September 28th, 2020 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 28th, 2020 Company Industry JurisdictionGREENWICH LIFESCIENCES, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Aegis Capital Corp. is acting as representative (the “Representative”), an aggregate of 1,260,870 authorized but unissued shares of common stock, par value $0.001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional 189,130 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.